Using GENEVA, we identified multiple drugs, genetic perturbations, and diseases that modulate the expression of ACE2, including cardiomyopathy, HNF1A overexpression, and drug treatments with RAD140 and itraconazole. This evidence concerns the gene HNF1A and cardiomyopathy.